Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Hypertension, Diabetes Mellitus, Dyslipi...
Phase NA
Enrollment 348
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The prevalence of dyslipidemia is high among patients with hypertension and diabetes mellitus, which increases the risk of cardiovascular disease. However, many patients lack awareness and adherence to treatment and lifestyle modifications. Therefore, a more structured and intensive approach to management and education is required. This study aims to implement intensive dyslipidemia management and education for patients registered at the Hanam City Hypertension and Diabetes Education Center and evaluate changes in blood lipid levels accordingly. Additionally, the study will analyze the impact of intensive education on patients' quality of life, health behaviors, and treatment adherence, ultimately contributing to the development of effective management strategies.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: centralized management and education group — If assigned to the test group (centralized management and education group), two instructors, one nurse and one nutritionist, will receive an hour of diabetes and high blood pressure 1:15, and will receive an hour of lipid disorder disease and impact 1:15 group education. You will receive a total of 2 hours of education, and you will receive 1 hour of lipid abnormality education conducted in 0 months through a visit in the third month. The dyslipidemia education was conducted in the form of 1:15 small group education or 1:87 group education, which was conducted in 0 months. In particular, the 1:87 form of large-scale education will be operated as a dialogue-oriented lecture that asks and answers questions, and will be conducted by doctors. And in 2 months and 4 months, education on diabetes, high blood pressure, and dyslipidemia will be shortened for 3 minutes through non-face-to-face management phone calls, not face-to-face.

Primary Outcomes

  • Change from Baseline in Total cholesterol, Triglyceride, HDL-cholesterol, LDL-cholesterol levels at 6 months (at baseline (pre-intervention) and at 6 months (after the intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-01
Completion: 2026-06-30
Eligibility
Age: 30 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 348 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Saint Vincent's Hospital, Korea
Collaborators: Hanam City Center for Hypertension and Diabetes Registration, Korean Center for Disease Control and Prevention
Contact Information
Study Contact:
Sung-Ho Her
+82312598397
hhhsungho@naver.com
Sung-Ho Her
82+031-249-7548
hhhsungho@naver.com
Catholic University of Korea, ST. Vincent's Hospital.
Interventions
  • Other: centralized management and education group — If assigned to the test group (centralized management and education group), two instructors, one nurse and one nutritionist, will receive an hour of diabetes and high blood pressure 1:15, and will receive an hour of lipid disorder disease and impact 1:15 group education. You will receive a total of 2 hours of education, and you will receive 1 hour of lipid abnormality education conducted in 0 months through a visit in the third month. The dyslipidemia education was conducted in the form of 1:15 small group education or 1:87 group education, which was conducted in 0 months. In particular, the 1:87 form of large-scale education will be operated as a dialogue-oriented lecture that asks and answers questions, and will be conducted by doctors. And in 2 months and 4 months, education on diabetes, high blood pressure, and dyslipidemia will be shortened for 3 minutes through non-face-to-face management phone calls, not face-to-face.
Study Locations (1 sites)
Catholic University of Korea, ST. Vincent's Hospital., Gyeonggi-do, Suwon-si 16247 South Korea
Eligibility Criteria
Inclusion Criteria: * Patients registered in the Hanam City Hypertension and Diabetes Program * Adults aged 30 to 80 years * Individuals who have provided written informed consent to participate in the study Exclusion Criteria: * Chronic kidney disease stage 4 or higher (eGFR \<30 mL/min/1.73m²) * Patients with liver cirrhosis or severe liver disease * Patients with a history of acute coronary syndrome within the past 6 months * Pregnant or breastfeeding women • Individuals with psychiatric disorders that may affect study participation
Conditions Portal Hypertension
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

Background Portal hypertension (PH) is a spectrum of complications of end-stage liver disease (ESLD) and cirrhosis, with severe manifestations including ascites and gastroesophageal varices. It is therefore important that timely and easily diagnosing PH has relevant prognostic and therapeutic implications. The current gold standard to evaluate PH is by hepatic vein catheterization using the transjugular approach, and measuring the hepatic venous pressure gradients (HVPG). Time-resolved, three-dimensional, three-directional velocity-encoded MRI, also termed four-dimensional (4D) flow MRI, has been shown superior accuracy over conventional two-dimensional (2D) phase-contrast MRI, in particular for quantification of regurgitant volumes and severity of cardiac shunts. Recently, the investigators developed new imaging methods based on 4D flow MRI for visualization of the vasculature of the abdominal blood flow circulation including the portal vein. Using the newly developed computation fluid dynamics (CFD) model the investigators could determine the absolute local blood pressure in the portal vein. Preliminary data in healthy volunteers seem promising, however, data in patients with ESLD including the correlation with invasively measured HVPG are lacking. Objectives The primary objective is to develop and validate noninvasive CFD and 4D Flow MRI based HVPG calculation to estimate portal pressure in patients with end-stage liver disease (ESLD). Methods In 50 adult patients with ESLD, submitted for liver transplantation (LT) screening, HVPG measurements using the transjugular approach according to the standard LT screening protocol, will be extended by 4D flow MRI measurements. Anticipated results In patients with ESLD, portal pressure can be measured by 4D flow MRI and will replace the invasive transjugular approach. The measurements can be directly incorporated in the LT screening. Moreover, the possibility to easily measure portal pressure will be relevant for all patients with ESLD at risk for PH. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients will undergo a single non-invasive MRI-examination of one hour long after a four hour period of fasting. The risks associated with non-invasive MRI examinations is neglectable.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Magnetic Resonance Imaging — MRI scans including abdominal 4D Flow MRI.

Primary Outcomes

  • Noninvasive HVPG (Within 4 years after enrollment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-12-01
Completion: 2026-12-01
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Leiden University Medical Center
Principal Investigators:
  • Hildo J Lamb, PhD, MD (PRINCIPAL_INVESTIGATOR) - Leiden University Medical Center
Contact Information
Study Contact:
Hildo J Lamb, PhD, MD
715269111
h.j.lamb@lumc.nl
Maarten E Tushuizen, PhD, MD
715269111
levertransplantatie@lumc.nl
Hildo J Lamb, PhD, MD
715269111
h.j.lamb@lumc.nl
Leiden University Medical Center
Interventions
  • Diagnostic Test: Magnetic Resonance Imaging — MRI scans including abdominal 4D Flow MRI.
Study Locations (1 sites)
Leiden University Medical Center, Leiden, South Holland 2333ZA Netherlands
Eligibility Criteria
Inclusion Criteria: * Eligible for liver transplantation (LT) screening (which excludes pregnancy). * Age ≥ 18 years and ≤ 75 (since \>75 is a contraindication for LT). * Written informed consent. Exclusion Criteria: * Exclusion criteria for MRI (claustrophobia, pacemaker, metal implants, etc.). * A psychiatric, addictive or any other disorder that compromises the subjects ability to understand the study content and to give written informed consent for participation in the study.
Conditions Hypertension, Obesity
Phase EARLY_PHASE1
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to understand how the nervous system communicates to blood vessels to increase blood pressure during stress. The study will also investigate how hypertension and obesity influence the nervous system and vascular function. The study will involve measuring sympathetic nervous system activity and blood flow during common laboratory physiological stress protocols (e.g. hypoxia, exercise), and in response to infusion of drugs that cause vasodilation or vasoconstriction.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Drug: Neuropeptide Y — intra-arterial infusion of neuropeptide Y

Primary Outcomes

  • Blood flow measured by doppler ultrasound (Acutely on the day of study)
  • Muscle sympathetic nervous system activity (Acutely on the day of study)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2021-07-18
Completion: 2026-12-31
Eligibility
Age: 18 Years – 55 Years
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Texas Southwestern Medical Center
Contact Information
Study Contact:
Christopher M Hearon, Ph.D.
214-345-4624
christopher.hearon@utsouthwestern.edu
Mary Childers
214-345-6459
marychilders@texashealth.org
CHristopher Hearon
8155405612
christopherhearon@texashealth.org
University of Texas Southwestern Medical Center
Interventions
  • Drug: Neuropeptide Y — intra-arterial infusion of neuropeptide Y
Study Locations (1 sites)
University of Texas Southwestern Medical Center, Dallas, Texas 75231 United States
Eligibility Criteria
Inclusion Criteria: * Control - BMI\<30, age 18-55 * Hypertensive - BMI\<30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring Obese- BMI\>30, age 18-55 Obese-hypertensive- BMI\>30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring Exclusion Criteria: All groups - presence of other significant cardiovascular disease, renal disease, history of smoking, diabetes,
Conditions Insomnia Disorder, Diabetes, Hypertensio...
Phase NA
Enrollment 320
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to apply traditional auricular press-needle acupuncture to treat sleep disturbances in elderly patients (aged ≥65 years) with comorbid diabetes mellitus and hypertension in rural areas of China. Given the complex bidirectional relationship between diabetes mellitus with hypertension and sleep disturbances, this cluster randomized trial is designed to test whether a village doctor-led intervention model supported by telemedicine can improve sleep disturbances in patients with comorbid diabetes mellitus and hypertension, compared to sham auricular press-needle acupuncture. Participants will be recruited by local village doctors according to the inclusion and exclusion criteria. The protocol is based on Traditional Chinese Medicine theory for core point selection: Heart, Liver, Kidney, Shenmen, and Forehead area, along with optimized medication regimens supported by remote cardiovascular specialists. The investigators will evaluate the overall improvement in sleep disturbances using the Pittsburgh Sleep Quality Index (PSQI) at the end of the 6-week treatment period, and assess sleep disturbances, anxiety, depression, daytime sleepiness, and fatigue at 12 weeks.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Auricular Acupuncture Therapy — Point Selection: Heart, Liver, Kidney, Shenmen, Forehead.① The patient sits, and the ear is disinfected with alcohol. ② The practitioner's hands and the local point area are routinely disinfected. Use Huatuo brand imported sterile disposable press needles (with release paper, Medical Device Registration No.: Su Xie Zhu Zhun 20162200966), specification 0.22×1.5mm. ③ After inserting the needle body into the aforementioned points, remove the release paper and gently press the adhesive tape to ensure tight adhesion. After needling, the village doctor presses the embedded needle site to induce a "deqi" sensation.
  • Device: Sham Auricular Acupuncture Group — Point Selection: The same locations on the ear as the experimental group. Procedure: Use press needles identical in appearance to the treatment group but without needle tips, applied to the point locations. The operation procedure, disinfection, replacement frequency, and pressing instructions are completely consistent with the experimental group. Avoid inducing a "deqi" sensation during the procedure. Key point: The patient is also instructed to press the points.

Primary Outcomes

  • Change in Pittsburgh Sleep Quality Index (PSQI)score from baseline to Week 6 (T1). (From enrollment to the end of treatment at 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-22
Completion: 2027-02-20
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 320 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jiangsu Taizhou People's Hospital
Contact Information
Study Contact:
Zhimei Teng
zhimei teng, master
0523-89890056
985292358@qq.com
Taizhou People's Hospital affiliated to Nanjing Medical University
Interventions
  • Device: Auricular Acupuncture Therapy — Point Selection: Heart, Liver, Kidney, Shenmen, Forehead.① The patient sits, and the ear is disinfected with alcohol. ② The practitioner's hands and the local point area are routinely disinfected. Use Huatuo brand imported sterile disposable press needles (with release paper, Medical Device Registration No.: Su Xie Zhu Zhun 20162200966), specification 0.22×1.5mm. ③ After inserting the needle body into the aforementioned points, remove the release paper and gently press the adhesive tape to ensure tight adhesion. After needling, the village doctor presses the embedded needle site to induce a "deqi" sensation.
  • Device: Sham Auricular Acupuncture Group — Point Selection: The same locations on the ear as the experimental group. Procedure: Use press needles identical in appearance to the treatment group but without needle tips, applied to the point locations. The operation procedure, disinfection, replacement frequency, and pressing instructions are completely consistent with the experimental group. Avoid inducing a "deqi" sensation during the procedure. Key point: The patient is also instructed to press the points.
Study Locations (1 sites)
Taizhou People's Hospital affiliated to Nanjing Medical University, Taizhou, Jiangsu 225300 China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥65 years; 2. Patients with comorbid diabetes mellitus and hypertension: 3. Sleep disturbance: Pittsburgh Sleep Quality Index (PSQI) total score ≥8; 4. Willing to participate in this study and sign the informed consent form; 5. Has resided in this village for at least six months. Exclusion Criteria: 1. Stroke; 2. Severe mental illness or cognitive impairment; 3. Severe organ failure (e.g., end-stage renal disease); 4. Ear infection, eczema, breakage, or deformity; 5. Currently receiving regular other acupuncture treatments; 6. Use of any hypnotic medications within the past month 7. Bleeding disorders or use of anticoagulants (increased bleeding risk); 8. History of fainting during acupuncture; 9. Life expectancy less than six months.

Berlin-Brandenburg Pregnancy Cohort

NCT03313024
Recruiting
Conditions Preeclampsia, Pregnancy Complications, D...
Phase Not Applicable
Enrollment 1580
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This study will investigate the interplay of different immune cells and placental cells as well as their potential for the development of pregnancy complications. In particular, the translation of the uteroplacental syndrome into a maternal syndrome, considered in the multifactorial pregnancy disorder preeclampsia, will be investigated. Immune cell subtypes are causally involved in the formation and translation of preeclampsia by inducing an endothelial dysfunction which leads to cardiovascular damage.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • T cell population content at the time of preeclampsia diagnosis compared to controls and verified by flow cytometry (at the time of preeclampsia diagnosis compared to controls at the same time point in pregnancy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2017-09-26
Completion: 2027-10
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: true
Enrollment: 1580 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Charite University, Berlin, Germany
Contact Information
Study Contact:
Florian Herse, PhD
+49 30 450 540 434
florian.herse@charite.de
Florian Herse, PhD
+49 30 450 540 434
florian.herse@charite.de
Experimental and Clinical Research Center (ECRC)
Florian Herse, PhD
Experimental and Clinical Research Center (ECRC)
Interventions
N/A
Study Locations (1 sites)
Experimental and Clinical Research Center (ECRC), Berlin, 13125 Germany
Eligibility Criteria
Inclusion Criteria: * healthy pregnant women after giving informed consent * pregnant with diagnosis of preeclampsia, gestational hypertension or gestational diabetes Exclusion Criteria: * infections * alcohol and drug abuse * manifest and chronic diseases
Conditions Lung Transplant, Pulmonary Hypertension
Phase PHASE1
Enrollment 4
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to determine if transseptal extra-corporeal membrane oxygenation (ECMO) can bridge pulmonary hypertension- right heart failure (PH-RVF) patients to lung transplant safely.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Protek Solo Transseptal Cannula — The Protek Solo Transseptal Cannula ECMO cannula will be placed from the right femoral vein and the drainage cannula will be placed from either the left femoral vein or the right internal jugular vein.

Primary Outcomes

  • Survival until transplant (3 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-12-11
Completion: 2028-12
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 4 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Ian Makey, MD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
  • Mohammad E Alomari, MD (STUDY_DIRECTOR) - Mayo Clinic
Contact Information
Study Contact:
Ian A Makey, MD
9049531048
makey.ian@mayo.edu
Mohammad E Alomari, MD
9044283665
alomari.mohammad@mayo.edu
Ian Makey, MD
800-634-1417
makey.ian@mayo.edu
Mayo Clinic in Florida
Interventions
  • Device: Protek Solo Transseptal Cannula — The Protek Solo Transseptal Cannula ECMO cannula will be placed from the right femoral vein and the drainage cannula will be placed from either the left femoral vein or the right internal jugular vein.
Study Locations (1 sites)
Mayo Clinic in Florida, Jacksonville, Florida 32224 United States
Eligibility Criteria
Inclusion Criteria Patients that are listed for lung transplantation and have: * PH defined as: * Group 1 Pulmonary arterial hypertension (PAH): Mean pulmonary artery pressure (PAP) ≥ 20 mm Hg, pulmonary capillary wedge pressure (PCWP) \< 15 mm Hg, and pulmonary vascular resistance (PVR) ≥ 3 Wood units * Group 3 PH is defined as the presence of chronic lung disease (CLD) and/or hypoxia and mean pulmonary artery pressure (PAP) ≥ 20 mm Hg. * Secondary PH (WHO Group 3) or diagnosis of primary PH (WHO Group 1) (to include Eisenmenger syndrome). * Failing right ventricle function defined as: * a cardiac (CI) index \< 2.2 L/min/m\^2 despite continuous infusion of high dose inotropes defined as: * Inhaled nitric oxide \> 20 ppm and one of the following: * Dobutamine \> 10 ug/kg/min x 15 minutes or * Milrinone \> 0.5 ug/kg/min x 120 minutes or * Epinephrine \> 0.5 ug/kg/min x 15 minutes or * Norepinephrine \> 0.5 ug/kg/min x 15 minutes and have one of the following: 1. central venous pressure (CVP) \> 15 mm Hg 2. global RV dysfunction on echocardiography defined as one of the following: 1. a tricuspid annular plane systolic excursion score of \<14mm 2. an RV diameter at base \>42mm 3. RV short-axis or midcavity diameter \>35mm * Lactate greater than 3 mmol/L * Urine output \< 0.5 ml/kg/hour * Age \> 18 years old * BMI \<35 * Informed consent signed by self or legally authorized representative. Exclusion Criteria * INTERMACS 1 patients (Critical cardiogenic shock patient who is "crashing and burning", has life-threatening hypotension and rapidly escalating inotropic or pressor support, with critical organ hypoperfusion often confirmed by worsening acidosis and lactate levels) * End organ failure defined as: hepatic total bilirubin \>5 mg/dL based on lab data within 24 hours prior to transseptal ECMO initiation; renal creatinine \>4 mg/dLbased on lab data within the 24 hours prior to transseptal ECMO initiation * Evidence of acute neurologic injury * Active infection defined as two of the following WBC \>12,500, positive blood culture, fever * RA thrombus * Thrombolysis within the previous 30 days or known existing coagulopathy such as thrombocytopenia or hemoglobin diseases such as sickle cell anemia or thalassemia * Right heart failure from isolated pulmonary embolism * Right heart failure from coronary artery disease or from left heart failure (WHO Type 2) * Congenital forms of pulmonary hypertension such as tetralogy of fallot or pulmonary vein stenosis.
Conditions Idiopathic Pulmonary Hypertension
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to compare the effectiveness and safety of two treatment approaches for patients with severe pulmonary hypertension: standard targeted drug therapy alone, and a combination of standard targeted drugs plus Qishen Yiqi Dropping Pills over 52 weeks of treatment. Pulmonary hypertension is a chronic condition that raises blood pressure in the lung arteries, causing symptoms like shortness of breath, tiredness, and difficulty with physical activity. While targeted drug treatments are available, many patients still experience persistent symptoms and reduced quality of life. This study will enroll patients with severe pulmonary hypertension to see if adding Qishen Yiqi Dropping Pills to standard treatment can improve patient outcomes. Participants will be randomly assigned to one of two groups: the combination treatment group will receive Qishen Yiqi Dropping Pills plus standard targeted drugs, and the control group will receive standard targeted drugs alone. All participants will be followed for 52 weeks, during which we will regularly assess: * Changes in daily quality of life * How far participants can walk in 6 minutes, and their level of breathlessness after the walk * Changes in heart function and related blood test indicators * Any side effects or discomfort during treatment The primary goal of this study is to see if the combination treatment can improve patients' exercise capacity and quality of life more effectively than standard treatment alone. We will also monitor the safety of adding Qishen Yiqi Dropping Pills to standard therapy. All study procedures follow ethical regulations, and participants can withdraw from the study at any time without affecting their regular medical care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Qishen Yiqi Dropping Pills 0.5g Oral Three Times Daily + Targeted Therapy for Pulmonary Arterial Hypertension — Experimental Group: Qishen Yiqi Dropping Pills combined with standard PAH-targeted therapy. Qishen Yiqi Dropping Pills is an NMPA-approved Chinese patent medicine for cardiovascular diseases, each pill is 0.5g, main ingredients include astragalus membranaceus, salvia miltiorrhiza, panax notoginseng and dalbergia odorifera. Administration: 0.5g orally tid after meals. Targeted therapy follows \*2021 Chinese PAH Diagnosis and Treatment Guidelines\*, including one or more approved PAH-targeted agents at clinically recommended doses. Total treatment duration: 26weeks.
  • Drug: Standard Pulmonary Arterial Hypertension (PAH)-Targeted Therapy Alone — Control Group Intervention: Participants in this group receive standard pulmonary arterial hypertension (PAH)-targeted therapy alone, without additional Qishen Yiqi Dropping Pills. The targeted therapy regimen complies with the \*2021 Chinese Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension\*, including one or more clinically approved PAH-targeted agents (endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, or soluble guanylate cyclase stimulators) at standard recommended doses. The regimen is consistent with the participants' stable pre-enrollment treatment plan, or initiated per the protocol-specified dosing schedule, with no dose adjustment allowed during the study period unless required for safety reasons. The total treatment duration is 26 weeks, identical to the experimental group.

Primary Outcomes

  • Change from Baseline in 6-Minute Walk Distance (6MWD) at 52 Weeks (Baseline, 1 weeks, 8 weeks, 26 weeks,40weeks, 52weeks (end of treatment))
  • Change from Baseline in Seattle Angina Questionnaire (SAQ) Score at 52 Weeks (Baseline, 1 weeks, 8 weeks, 26 weeks,40weeks, 52weeks (end of follow-up))
  • Change from Baseline in Borg Rating of Perceived Exertion (RPE) Scale Score at 52 Weeks (Baseline, 1 weeks, 8 weeks, 26 weeks,40weeks,52weeks (end of follow-up))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-10-25
Completion: 2030-12-31
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guangdong Provincial People's Hospital
Contact Information
Study Contact:
Xuyu He, MD, PhD
86136322737312
hexuyu97@126.com
Xuyu H, Md,PhD
8613232273712
hexuyu97@126.com
Guangdong Provincial People's Hospital
Interventions
  • Drug: Qishen Yiqi Dropping Pills 0.5g Oral Three Times Daily + Targeted Therapy for Pulmonary Arterial Hypertension — Experimental Group: Qishen Yiqi Dropping Pills combined with standard PAH-targeted therapy. Qishen Yiqi Dropping Pills is an NMPA-approved Chinese patent medicine for cardiovascular diseases, each pill is 0.5g, main ingredients include astragalus membranaceus, salvia miltiorrhiza, panax notoginseng and dalbergia odorifera. Administration: 0.5g orally tid after meals. Targeted therapy follows \*2021 Chinese PAH Diagnosis and Treatment Guidelines\*, including one or more approved PAH-targeted agents at clinically recommended doses. Total treatment duration: 26weeks.
  • Drug: Standard Pulmonary Arterial Hypertension (PAH)-Targeted Therapy Alone — Control Group Intervention: Participants in this group receive standard pulmonary arterial hypertension (PAH)-targeted therapy alone, without additional Qishen Yiqi Dropping Pills. The targeted therapy regimen complies with the \*2021 Chinese Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension\*, including one or more clinically approved PAH-targeted agents (endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, or soluble guanylate cyclase stimulators) at standard recommended doses. The regimen is consistent with the participants' stable pre-enrollment treatment plan, or initiated per the protocol-specified dosing schedule, with no dose adjustment allowed during the study period unless required for safety reasons. The total treatment duration is 26 weeks, identical to the experimental group.
Study Locations (1 sites)
Guangdong Provincial People's Hospital, Guangzhou, Guagdong 515000 China
Eligibility Criteria
Inclusion Criteria: * 1\. Male or female participants aged between 18 and 75 years (inclusive) at the screening visit. 2\. Diagnosed with pulmonary arterial hypertension (PAH) classified according to the \*2021 Chinese Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension\*, and belonging to one of the following subgroups: * Subgroup Ⅰ: Idiopathic pulmonary arterial hypertension (IPAH) under the category of arterial pulmonary hypertension * Subgroup Ⅱ: Pulmonary hypertension secondary to left heart disease (congenital heart disease) 3. World Health Organization (WHO) Functional Class III or IV symptoms at screening. 4\. Meet all of the following hemodynamic criteria confirmed by right heart catheterization (RHC) at study screening: mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg. 5\. Able to walk a minimum of 100 meters and a maximum of 440 meters during the 6-Minute Walk Test (6MWT) at the screening visit; in addition, participants must demonstrate stable baseline 6MWT performance between the screening visit and the randomization visit. 6\. Participants with pulmonary hypertension who are either treatment-naïve or currently receiving treatment: for participants who have received prior treatment (defined as having used PAH-targeted therapeutic agents within 4 weeks before screening), mPAP ≥ 25 mmHg and PCWP ≤ 15 mmHg must be confirmed at the randomization visit. 7\. Able to understand study procedures, willing to comply with study restrictions, and willing and able to provide written informed consent prior to the initiation of all study-related procedures. Exclusion Criteria: * 1\. Meet any of the following criteria: 2. Diagnosed with Group 3 or Group 5 pulmonary hypertension (PH) according to the \*2021 Chinese Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension\*. 3\. Echocardiogram within 6 months before screening indicates left ventricular ejection fraction (LVEF) ≤ 40%, or clinically significant ischemic mitral or aortic valve disease, or constrictive heart disease as judged by the investigator. 4\. Presence of 3 or more of the following risk factors for left ventricular dysfunction: * Body mass index (BMI) ≥ 30 kg/m² at screening visit * History of essential hypertension * Diabetes mellitus of any type * History of significant coronary artery disease (CAD) confirmed by any of the following: * History of myocardial infarction * History of percutaneous coronary intervention (PCI) * Angiographic evidence of ≥ 50% stenosis in at least one major coronary artery * Positive cardiac stress imaging test * History of coronary artery bypass graft surgery (CABG) * History of chronic stable angina or unstable angina 5. Uncontrolled systemic arterial hypertension: systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg at randomization visit (Day 1). 6\. History of long QT syndrome or torsades de pointes ventricular tachycardia. 7. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3 times the upper limit of normal (ULN) at screening visit. 8\. Severe renal impairment: estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m² at screening calculated by the CKD-EPI formula. 9\. Severe hepatic impairment (Child-Pugh Class C) at screening visit, with or without cirrhosis; patients receiving renal dialysis or with a history of renal transplantation. 10\. Known coagulation defects, including: hereditary or acquired coagulation disorders (factor XII deficiency, factor XIII deficiency), reduced coagulation factor production due to acute or chronic liver disease, impaired coagulation efficiency caused by lupus anticoagulant, disseminated intravascular coagulation (DIC), or anticoagulant factor autoantibodies. 11\. Evidence or history of major hemorrhage or intracranial hemorrhage. 12. History of increased intracranial pressure. 13. Pregnant or lactating women. 14. Any surgical or medical condition that may significantly alter the absorption, distribution, metabolism, or excretion of any drug, including but not limited to: history of major gastrointestinal surgery deemed clinically significant by the investigator within 12 months before screening (e.g., gastrectomy, gastrointestinal stoma anastomosis, intestinal resection, gastric bypass surgery, gastroenterostomy, or gastric banding), current active inflammatory bowel disease, or history of active inflammatory bowel disease. 15\. Any surgical or medical condition not specified in the protocol that, in the investigator's opinion, would expose the patient to higher risk due to study participation, or may prevent the patient from complying with study requirements or completing the trial period. 16\. Patients who are unwilling or unable to safely discontinue current pulmonary arterial hypertension (PAH)-targeted medications during the study as required by the protocol. 17\. History of any contraindication or hypersensitivity reaction to any study drug or drugs with similar chemical structures. 18\. History of active substance abuse (including alcohol) within the past 1 year, or patients considered potentially unreliable by the investigator. 19\. Personnel directly involved in the conduct of this clinical study.
Conditions Portal Hypertension
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

Evaluation of non-invasive prognostic parameters in patients receiving transjugular intrahepatic portosystemic shunt (TIPS) for complications of portal hypertension. Patients are cared according to the local standardized follow up program. Clinical and laboratory data from standard patient care are evaluated for potential prognostic value.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: TIPS procedure — Implantation of TIPS for portal hypertension

Primary Outcomes

  • Survival (up to 10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-05-12
Completion: 2030-12-31
Eligibility
Age: 18 Years – 100 Years
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Bonn
Principal Investigators:
  • Michael Praktiknjo, MD (PRINCIPAL_INVESTIGATOR) - University of Bonn
Contact Information
Study Contact:
Michael Praktiknjo, MD
+49(0)228-287 15770
michael.praktiknjo@ukbonn.de
Johannes Chang, MD
+49(0)228-287 15770
johannes.chang@ukbonn.de
Michael Praktiknjo, MD
+49228 28715770
michael.praktiknjo@ukbonn.de
University Hospital Bonn
Interventions
  • Device: TIPS procedure — Implantation of TIPS for portal hypertension
Study Locations (1 sites)
University Hospital Bonn, Bonn, Germany
Eligibility Criteria
Inclusion Criteria: * Insertion of TIPS according to guidelines Exclusion Criteria: * Contraindication for TIPS
Conditions Essential Hypertension
Phase PHASE3
Enrollment 324
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Sacubitril∙Valsartan(dose maintenance) — During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treated 1 CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 placebo of CKD-202A(Sacubitril∙Valsartan) 200mg, 1 placebo of D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day.
  • Drug: Sacubitril∙Valsartan(dose increasing) — During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST2 pariticipants are treated 1 CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 CKD-202A(Sacubitril∙Valsartan) 200mg, 1 placebo of D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day.
  • Drug: Valsartan — During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST2 pariticipants are treated 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 placebo of CKD-202A(Sacubitril∙Valsartan) 200mg, 1 D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day.

Primary Outcomes

  • change from baseline in MASBP(Mean Ambulatory Systolic Blood Pressure) (10 weeks after baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-10-14
Completion: 2026-12-31
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 324 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chong Kun Dang Pharmaceutical
Contact Information
Study Contact:
Keehyun Ham, Project Leader
+82-2-2194-0479
hamki@ckdpharm.com
Byungsu Yoo, PI
+82-33-741-0917
yubs@yonsei.ac.kr
Wonju Severance Christian Hospital
Interventions
  • Drug: Sacubitril∙Valsartan(dose maintenance) — During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treated 1 CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 placebo of CKD-202A(Sacubitril∙Valsartan) 200mg, 1 placebo of D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day.
  • Drug: Sacubitril∙Valsartan(dose increasing) — During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST2 pariticipants are treated 1 CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 CKD-202A(Sacubitril∙Valsartan) 200mg, 1 placebo of D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day.
  • Drug: Valsartan — During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST2 pariticipants are treated 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 placebo of CKD-202A(Sacubitril∙Valsartan) 200mg, 1 D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day.
Study Locations (1 sites)
Wonju Severance Christian Hospital, Wŏnju, South Korea
Eligibility Criteria
Inclusion Criteria: * Participants who are 19 years old or older. * Participants who have voluntarily decided to participate in this clinical trial and signed ICF. Exclusion Criteria: * Participants with a history of secondary hypertension or suspected secondary hypertension. * Participants with a orthostatic hypotension. * Participants who require combination administration of antihypertensive drugs other than clinical trial drugs during the clinical trial participation period. * Participants with type 1 diabetes or poorly controlled diabetes. * Participants who treated other clinical trial drugs within 4 weeks of screening visit. * Participants with a history of drug or alcohol abuse or suspected patient within 24 weeks as of the time of screening * Pregnant women, lactating women, or Subjects who do not agree to use appropriate contraception during the clinical trial period and for two weeks after the end of administration of the last clinical trial drug * Participants who are unable to participate in this clinical trial at the discretion of the investigator.
Conditions Pulmonary Arterial Hypertension
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

Pulmonary arterial hypertension (PAH) is a rare and severe disease characterized by elevation of pulmonary artery pressure (PAP) and increased pulmonary vascular resistance (PVR) due to the narrowing of small pulmonary arteries. The European Society of Cardiology (ESC) and the European Respiratory Society (ERS) recommend supervised exercise-based rehabilitation as part of the treatment of PAH patients alongside optimal medical therapy (Level of evidence A, Class of recommendation I). Studies on exercise-based rehabilitation for PAH patients are limited, and most interventions have been conducted at least partially in hospital settings. Unlike more common cardiovascular diseases, there are no detailed international exercise guidelines tailored specifically for PAH patients. This study aims to verify that a group-based outpatient rehabilitation protocol suitable for the Finnish healthcare system improves exercise capacity, quality of life, and physical activity of PAH patients and is safe for appropriately selected patients. Additionally, the study aims to determine whether PAH patients adhere to regular exercise training and whether physical activity increases in the long term. The goal is to assess whether an outpatient rehabilitation protocol, designed for the Finnish healthcare system, can achieve similar results to those observed in previous international studies. The primary outcome measure is the change in the six-minute walking distance (6MWD) compared to the patient's baseline. Long-term 6MWD data are often available for patients. The 6MWD is the most commonly used primary outcome in randomized and controlled PAH drug trials, and improvements in this test have been the basis for drug approvals. An improvement of 33 meters in the 6MWD is considered clinically significant, and the goal is to achieve this change with group-based outpatient rehabilitation. Secondary outcomes include changes in quality of life (SF-36), WHO functional class, NT-proBNP levels, echocardiographic parameters, ESC/ERS risk-stratification score (four-strata model), muscle strength, respiratory measures, balance, daily step count, and insomnia severity.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: EXERCISE TRAINING WITH OR WITHOUT MEDICATION — Patients are counseled how to do endurance training and strenght training at home by a trained physiotherapist.

Primary Outcomes

  • Change in six-minute walking test result (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-27
Completion: 2027-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tampere Heart Hospital
Collaborators: Tampere University Hospital, Tampere University
Principal Investigators:
  • Jussi A Hernesniemi, MD PhD (STUDY_CHAIR) - Tampere Heart Hospital
Contact Information
Study Contact:
Pauliina Leskelä, MD
+3583311611
pauliina.leskela@sydansairaala.fi
Jussi A Hernesniemi, MD PhD
+3583311611
jussi.hernesniemi@sydansairaala.fi
Kati Helleharju, Research cordinator
+3583311611
kati.helleharju@sydansairaala.fi
Tampere Heart Hospital
Interventions
  • Behavioral: EXERCISE TRAINING WITH OR WITHOUT MEDICATION — Patients are counseled how to do endurance training and strenght training at home by a trained physiotherapist.
Study Locations (1 sites)
Tampere Heart Hospital, Tampere, Pirkanmaa 33300 Finland
Eligibility Criteria
Inclusion Criteria: * Adults over 18 years old residing in Tampere or nearby municipalities. * WHO functional classification II-III. * Commitment to the exercise program. * Stable disease condition with no PAH medication changes in the two months prior. * No recent syncope or arrhythmias causing symptoms within the past two months. Exclusion Criteria: * Severe pulmonary disease or left ventricular failure (HFrEF). * Pregnancy. * Severe congenital heart defect (Eisenmenger syndrome). * Severe liver disease. * Acute inflammatory condition. * Severe anemia (hemoglobin ≤ 75% of the lower reference limit). * Systolic blood pressure below 85 mmHg. * Recent syncope. * Other significant conditions affecting physical capacity, such as severe neurological diseases or musculoskeletal issues. * Untreated severe arrhythmias. * Changes in PAH medication during the rehabilitation program.
Conditions Advanced Solid Tumor, Metastatic Solid T...
Phase PHASE1, PHASE2
Enrollment 358
Locations 11 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: GI-102 subcutaneous (SC) — 0.12 mg/kg, 0.24 mg/kg or Recommended phase 2 dose of GI-102 will be administered via SC injection Q3W up to 2 years (approximately 35 years).
  • Drug: GI-102 — Dose level will be escalated from 0.06 mg/kg to 0.45 mg/kg and Recommended phase 2 dose (or RP2D-1, RP2D+1) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
  • Drug: doxorubicin — Doxorubicin will be administered intravenously at a dose of 75 mg/m2 on Day 3 every 3-week (21-day) cycle for up to 6 cycles.
  • Drug: paclitaxel — Paclitaxel will be administered intravenously over 1 hour at a dose of 80 mg/m2 each time weekly as a diluted solution according to the prescribing information.
  • Drug: bevacizumab — Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.
  • Drug: eribulin — Eribulin will be administered intravenously at a dose of over 1.4 mg/m2 over 2 to 5 minutes on Days 3 and 10 every 3-week (21-day) cycle.
  • Drug: trastuzumab deruxtecan (T-DXd) — T-DXd will be administered initially as a 5.4 mg/kg (or 6.4 mg/kg only for gastric cancer) IV over 30 - 90 minutes every 3 weeks.
  • Drug: pembrolizumab — pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.

Primary Outcomes

  • Incidence and nature of Dose-Limiting Toxicity (DLTs) (dose escalation phase of Part A and B) (Study Day 1, assessed up to DLT period (3 weeks after treatment))
  • Incidence, nature, and severity of adverse events (AEs) and immune-related AEs (irAEs) (dose escalation phase of Part A and B) (Study Day 1, assessed up to approximately 24 months)
  • Objective Response Rate (ORR) (dose optimization phase of Part A, dose expansion phase of Part B, Part C and D) (Study Day 1, assessed up to approximately 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2023-05-30
Completion: 2027-04-24
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 358 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: GI Innovation, Inc.
Collaborators: Merck Sharp & Dohme LLC
Principal Investigators:
  • Nari Yun, PhD (STUDY_DIRECTOR) - GI Innovation, Inc.
Contact Information
Study Contact:
Jay Kim
+82-2-404-2003
Clinical-102@gi-innovation.com
Woosun Lee
+82-2-404-2003
Clinical-102@gi-innovation.com
Mahesh Seetharam, MD
Mayo Clinic in Arizona
Interventions
  • Drug: GI-102 subcutaneous (SC) — 0.12 mg/kg, 0.24 mg/kg or Recommended phase 2 dose of GI-102 will be administered via SC injection Q3W up to 2 years (approximately 35 years).
  • Drug: GI-102 — Dose level will be escalated from 0.06 mg/kg to 0.45 mg/kg and Recommended phase 2 dose (or RP2D-1, RP2D+1) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
  • Drug: doxorubicin — Doxorubicin will be administered intravenously at a dose of 75 mg/m2 on Day 3 every 3-week (21-day) cycle for up to 6 cycles.
  • Drug: paclitaxel — Paclitaxel will be administered intravenously over 1 hour at a dose of 80 mg/m2 each time weekly as a diluted solution according to the prescribing information.
  • Drug: bevacizumab — Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.
Study Locations (11 sites)
Mayo Clinic in Arizona, Scottsdale, Arizona 85259 United States
Mayo Clinic in Florida, Jacksonville, Florida 32224 United States
Mayo Clinic in Minnesota, Rochester, Minnesota 55905 United States
Memorial Sloan-Kettering Cancer Center, New York, New York 10065 United States
Cleveland Clinic, Cleveland, Ohio 44195 United States
Seoul National University Hospital, Seoul, Seoul 03080 South Korea
St. Vincent's Hospital, Suwon, suwon 12647 South Korea
Yonsei University Health System, Severance Hospital, Seoul, 03722 South Korea
Yonsei University Health System, Severance Hospital, Seoul, 03722 South Korea
Asan Medical Center, Seoul, 05505 South Korea
Eligibility Criteria
Key Inclusion Criteria: * Males and females aged ≥ 18 years (or ≥ 19 years according to local regulatory guidelines) at the time of screening. * Has adequate organ and marrow function as defined in protocol. * Measurable disease as per RECIST v1.1. * ECOG performance status 0-1. * Adverse events related to any prior chemotherapy, radiotherapy, immunotherapy, other prior systemic anti-cancer therapy, or surgery must have resolved to Grade ≤1, except alopecia and Grade 2 peripheral neuropathy. * HIV infected patients must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease as defined in protocol. Key Exclusion Criteria: * Has known active CNS metastases and/or carcinomatous meningitis. * An active second malignancy. * Has active or a known history of Hepatitis B or known active Hepatitis C virus infection. * Has active tuberculosis or has a known history of active tuberculosis. * Active or uncontrolled infections, or severe infection within 4 weeks before study treatment administration. * History of chronic liver disease or evidence of hepatic cirrhosis, except patients with liver metastasis. * Has an active autoimmune disease that has required systemic treatment in past 2 years. * Previous immunotherapies related to mode of action of GI-102. * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive medications within 2 weeks prior to Cycle 1 Day 1. * Administration of prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment. * Radiotherapy within the last 2 weeks before start of study treatment administration, with exception of limited field palliative radiotherapy. * Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1. * Known hypersensitivity to any of the components of the drug products and/or excipients of GI-102. Other protocol defined inclusion exclusion criteria may apply
Conditions Breast Cancer
Phase PHASE3
Enrollment 158
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This study will compare morphine consumption during the first 48 hours postoperatively between the OFA group and the CA control group.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Dexmedetomidine — Dexmedetomidine+Lidocaine

Primary Outcomes

  • comparison of Morphine consumption in the two groups (during the first 48 hours postoperatively)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2022-12-07
Completion: 2027-06-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 158 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut Curie
Principal Investigators:
  • Mary SAAD, MD (STUDY_DIRECTOR) - Institut Curie Saint-Cloud
Contact Information
Study Contact:
Anne-Claire COYNE, PhD
0033156245765
anne-claire.coyne@curie.fr
Mary SAAD, MD
0033147112371
mary.saad@curie.fr
Jane Muret, MD
jane.muret@curie.fr
Institut Curie Paris
Interventions
  • Drug: Dexmedetomidine — Dexmedetomidine+Lidocaine
Study Locations (3 sites)
Institut Curie Paris, Paris, 75005 France
Institut Curie Saint-Cloud, Saint-Cloud, 92210 France
Gustave Roussy, Cancer Campus, Grand Paris, Villejuif, France
Eligibility Criteria
Inclusion Criteria: 1. Women aged 18 or older. 2. Patients with a French health insurance coverage (having a French social security number). 3. Patient eligible for free flap reconstruction surgery of the breastunder general anaesthesia. 4. Patient who has given written consent to participate in accordance with the regulations. 5. Having a negative blood pregnancy test for patients of childbea ring age. Exclusion Criteria: 1. Allergy or intolerance to any of the drugs (dexmedetomidine, remifentanil, lidocaine, propofol, dexamethasone, kétamine, ketoprofen, nefopam, paracetamol, morphine, ropivacaine, droperidol, ondansetron). 2. Known history of heart failure, arrhythmias and/or ischemic heart disease and/or severe renal insufficiency. 3. Pulse below 50bpm during anaesthesia consultation and/or under beta blocker treatment. 4. Treatment with ACEI/ARB. 5. Severe asthma. 6. Symptomatic gastric or duodenal ulcer with or without treatment. 7. Baseline systolic blood pressure \< 100 mmHg. 8. Chronic preoperative pain and/or use of WHO ladder step 2 or 3 analgesics preoperatively. 9. Patient already included in another therapeutic trial evaluating an experimental molecule. 10. Persons deprived of liberty or under guardianship. 11. Patients with suspected difficulties in assessing pain on a scale. 12. Inability to undergo trial medical monitoring due to geographic, social or psychological reasons.